Table 2.
Comparison of adverse events in the sorafenib and sunitinib groups
| Adverse event | Sorafenib group [cases (%)] | Sunitinib group [cases (%)] | P value* | ||||
|---|---|---|---|---|---|---|---|
| All grade | Grade 1–2 | Grade 3–4 | All grade | Grade 1–2 | Grade 3–4 | ||
| Hypertension | 23 (20.9) | 22 (20.0) | 1 (0.9) | 23 (36.0) | 20 (32.4) | 3 (3.6) | 0.050 |
| Hand–foot syndrome | 74 (67.3) | 66 (60.0) | 8 (7.3) | 44 (59.5) | 44 (59.5) | 0 (0.0) | 0.279 |
| Diarrhea | 69 (62.7) | 67 (60.9) | 2 (1.8) | 26 (35.2) | 23 (31.1) | 3 (4.1) | <0.001 |
| Nausea | 41 (37.3) | 41 (37.3) | 0 (0.0) | 29 (39.2) | 29 (39.2) | 0 (0.0) | 0.793 |
| Fatigue | 42 (38.2) | 42 (38.2) | 0 (0.0) | 33 (44.6) | 33 (44.6) | 0 (0.0) | 0.385 |
| Alopecia | 9 (8.2) | 9 (8.2) | 0 (0.0) | 7 (9.5) | 7 (9.5) | 0 (0.0) | 0.763 |
| Leukocytopenia | 12 (10.9) | 12 (10.9) | 0 (0.0) | 27 (36.5) | 24 (32.4) | 3 (4.1) | <0.001 |
| Anemia | 20 (18.2) | 18 (16.4) | 2 (1.8) | 9 (12.2) | 9 (12.2) | 0 (0.0) | 0.272 |
| Thrombocytopenia | 12 (10.9) | 12 (10.9) | 0 (0.0) | 30 (40.5) | 28 (37.8) | 2 (2.7) | <0.001 |
| Hypothyroidism | 4 (3.6) | 4 (3.6) | 0 (0.0) | 13 (17.6) | 13 (17.6) | 0 (0.0) | 0.001 |
| Elevation of ALT | 11 (10.0) | 10 (9.1) | 1 (0.9) | 10 (13.5) | 10 (13.5) | 0 (0.0) | 0.462 |
ALT alanine aminotransferase
* Grade 1–2 and grade 3–4 toxicities were combined for the comparison